(Q42217179)

18 October 2017

title

An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy (English)

1 reference

18 October 2017

1 reference

4

Tanuja Chitnis

1 reference

18 October 2017

5

Howard L Weiner

1 reference

18 October 2017

Robert L Carruthers

1

1 reference

18 October 2017

Dalia L Rotstein

series ordinal

2

1 reference

18 October 2017

Brian C Healy

series ordinal

3

1 reference

18 October 2017

Guy J Buckle

series ordinal

6

1 reference

18 October 2017

publication date

22 May 2014

1 reference

Multiple Sclerosis Journal

18 October 2017

published in

1 reference

18 October 2017

volume

20

1 reference

18 October 2017

issue

10

1 reference

18 October 2017

page(s)

1381-1390

1 reference

Fingolimod for multiple sclerosis

18 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

Progressive multifocal leukoencephalopathy after natalizumab monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

Long term benefit of multiple sclerosis treatment: an investigation using a novel data collection technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

A method for evaluating treatment switching criteria in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

Postmarketing evidence of disease-modifying drugs in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

Long-term follow-up of clinical trials of multiple sclerosis therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

What can be learned from open direct comparative trials in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

Lack of JC viral genomic sequences in multiple sclerosis brain tissue by polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

Persistence of DNA Sequences of BK Virus and JC Virus in Normal Human Tissues and in Diseased Tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

In vitro-labeled DNA for detecting viral genomes in multiple sclerosis: I. papovaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

JC virus in cerebrospinal fluid samples of multiple sclerosis patients at the first demyelinating event.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

Detection of viral DNA sequences in the cerebrospinal fluid of patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514535282

21 January 2018

Identifiers

DOI

10.1177/1352458514535282

1 reference

18 October 2017

1 reference